Arrowhead's Plozasiran Shows 100% Reduction in Acute Pancreatitis Events in High-Risk Patients
Event summary
- Arrowhead Pharmaceuticals presented Phase 3 SHASTA-3 and SHASTA-4 data showing plozasiran reduced acute pancreatitis events by 78% versus placebo in severe hypertriglyceridemia patients.
- In the highest-risk subgroup (TG above 880 mg/dL with prior pancreatitis history), plozasiran achieved a 100% reduction in events versus placebo.
- The studies met all primary and secondary endpoints, with median triglyceride reductions of 79% and 81% at Month 12.
- Arrowhead plans to seek regulatory approval for plozasiran in the broader severe hypertriglyceridemia population by the end of 2026.
The big picture
Arrowhead's Phase 3 data positions plozasiran as a potential game-changer in severe hypertriglyceridemia treatment, addressing a critical unmet need for patients at high risk of acute pancreatitis. The results strengthen Arrowhead's case for regulatory approval and commercial expansion, potentially broadening the drug's addressable market beyond its current FCS indication. The strategic acquisition of an FDA Priority Review Voucher underscores the company's aggressive push to bring this therapy to market swiftly.
What we're watching
- Regulatory Pathway
- Whether the FDA Priority Review Voucher will accelerate plozasiran's approval timeline for the broader severe hypertriglyceridemia population.
- Market Differentiation
- How plozasiran's quarterly dosing and favorable safety profile will position it against existing treatments in the severe hypertriglyceridemia space.
- Commercial Strategy
- The pace at which Arrowhead can expand plozasiran's commercial reach beyond familial chylomicronemia syndrome (FCS) into the larger severe hypertriglyceridemia market.